p53 Review Article

You have free access to this content

The TP53 gene, tobacco exposure, and lung cancer†

  1. Shinichi Toyooka1,3,
  2. Toshihide Tsuda4,
  3. Adi F. Gazdar1,2,*

Article first published online: 24 FEB 2003

DOI: 10.1002/humu.10177

Issue

Human Mutation

Human Mutation

Special Issue: Focus on p53 and Cancer

Volume 21, Issue 3, pages 229–239, March 2003

Additional Information

How to Cite

Toyooka, S., Tsuda, T. and Gazdar, A. F. (2003), The TP53 gene, tobacco exposure, and lung cancer. Hum. Mutat., 21: 229–239. doi: 10.1002/humu.10177

Author Information

  1. 1

    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas

  2. 2

    Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas

  3. 3

    Department of Cancer and Thoracic Surgery, Okayama University, Graduate School of Medicine and Dentistry, Okayama, Japan

  4. 4

    Department of Hygiene and Preventive Medicine, Okayama University, Graduate School of Medicine and Dentistry, Okayama, Japan

*Hamon Center for Therapeutic Oncology Research, University of Texas South-western Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-8593

  1. †

    For the p53 Special Issue

Publication History

  1. Issue published online: 24 FEB 2003
  2. Article first published online: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (274K)

REFERENCES

  • Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wu L, Decker PA, Jen J, Sidransky D. 1999. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer [see comments]. J Natl Cancer Inst 91:332–339.
  • Ahrendt SA, Chow JT, Yang SC, Wu L, Zhang MJ, Jen J, Sidransky D. 2000. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res 60:3155–3159.
  • Baptiste N, Friedlander P, Chen X, Prives C. 2002. The proline-rich domain of p53 is required for cooperation with anti- neoplastic agents to promote apoptosis of tumor cells. Oncogene 21:9–21.
  • Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane DP, Metcalf RA, Samet JM, Takeshima Y, Gu JR, et al. 1993a. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 53:4817–4822.
  • Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane DP, Metcalf RA, Samet JM, Takeshima Y, Gu JR, Vahakangas KH, Soini Y, Paakko P, Welsh JA, Trump BF, Harris CC. 1993b. p53 protein accumalates frequently in early bronchial neoplasia. Cancer Res 53:4817–4822.
  • Beroud C, Soussi T. 2003. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21:176–181.
    Direct Link:
  • Blons H, Laurent-Puig P. 2003. TP53 and head and neck neoplasms. Hum Mutat 21:252–257.
    Direct Link:
  • Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF, Linnoila RI. 1992. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743–749.
  • Bouck N. 1996. P53 and angiogenesis. Biochim Biophys Acta 1287:63–66.
  • Carbone M, Kratzke RA, Testa JR. 2002. The pathogenesis of mesothelioma. Semin Oncol 29:2–17.
  • Caron de Fromentel C, Soussi T. 1992. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4:1–15.
    Direct Link:
  • Cheng YW, Hsieh LL, Lin PP, Chen CP, Chen CY, Lin TS, Su JM, Lee H. 2001. Gender difference in DNA adduct levels among nonsmoking lung cancer patients. Environ Mol Mutagen 37:304–310.
    Direct Link:
  • Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, Ritchey DM, Miller YE. 1997. Widely dispersed p53 mutation in respiratory epithelium. J Clin Invest 100:2133–2137.
  • Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA. 1993. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 53:4129–4133.
  • Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. 1994. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287–2291.
  • Gao HG, Chen JK, Stewart J, Song B, Rayappa C, Whong WZ, Ong T. 1997. Distribution of p53 and K-ras mutations in human lung cancer tissues. Carcinogenesis 18:473–478.
  • Giatromanolaki A, Koukourakis MI. 1998. p53 and angio-genesis in non-small-cell lung cancer. Br J Cancer 77:850–852.
  • Guinee Jr., Travis WD, Trivers GE, De Benedetti VM, Cawley H, Welsh JA, Bennett WP, Jett J, Colby TV, Tazelaar H, et al. 1995. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis 16:993–1002.
  • Hainaut P, Olivier M, Pfeifer GP. 2001. TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. Mutagenesis 16:551–553.
  • Hainaut P, Pfeifer GP. 2001. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 22:367–374.
  • Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57–70.
  • Harris CC. 1996. p53 tumor suppressor gene: from the basic research laboratory to the clinic: an abridged historical perspective. Carcinogenesis 17:1187–1198.
  • Hecht SS. 2002. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 3:461–469.
  • Higashiyama M, Kodama K, Yokouchi H, Takami K, Doi O, Kobayashi H, Tanisaka K, Minamigawa K. 1998. Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs. J Surg Oncol 68:19–24.
    Direct Link:
  • Hollstein M, Bartsch H, Wesch H, Kure EH, Mustonen R, Muhlbauer KR, Spiethoff A, Wegener K, Wiethege T, Muller KM. 1997. p53 gene mutation analysis in tumors of patients exposed to alpha- particles. Carcinogenesis 18:511–516.
  • Hussain SP, Kennedy CH, Amstad P, Lui H, Lechner JF, Harris CC. 1997. Radon and lung carcinogenesis: mutability of p53 codons 249 and 250 to 238Pu alpha-particles in human bronchial epithelial cells. Carcinogenesis 18:121–125.
  • Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, Harris CC. 2001a. Mutability of p53 hotspot codons to benzoapyrene diol epoxide BPDE and the frequency of p53 mutations in nontumorous human lung. Cancer Res 61:6350–6355.
  • Hussain SP, Hofseth LJ, Harris CC. 2001b. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 34(Suppl 2):S7–S15.
  • Jonas S, Windeatt SA, OB Fordy C, Allen-Mersh TG. 1996. Identification of carcinoembryonic antigen-producing cells circulating in the blood of patients with colorectal carcinoma by reverse transcriptase polymerase chain reaction. Gut 39:717–721.
  • Kerr KM, Carey FA, King G, Lamb D. 1994. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53, and c-erbB-2 expression. J Pathol 174:249–256.
    Direct Link:
  • Kitaguchi S, Takeshima Y, Nishisaka T, Inai K. 1998. Proliferative activity, p53 expression and loss of heterozygosity on 3p, 9p and 17p in atypical adenomatous hyperplasia of the lung. Hiroshima J Med Sci 47:17–25.
  • Kitamura H, Kameda Y, Nakamura N, Nakatani Y, Inayama Y, Iida M, Noda K, Ogawa N, Shibagaki T, Kanisawa M. 1995. Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. Am J Pathol 146:876–887.
  • Kitamura H, Kameda Y, Ito T, Hayashi H. 1999. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol 111:610–622.
  • Laudanski J, Niklinska W, Burzykowski T, Chyczewski L, Niklinski J. 2001. Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer. Eur Respir J 17:660–666.
  • Liu BC, Fu DC, Miao Q, Wang HH, You BR. 1998. p53 gene mutations in asbestos associated cancers. Biomed Environ Sci 11:226–232.
  • Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D. 1994. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 54:1634–1637.
  • Mao L. 2001. Molecular abnormalities in lung carcinogenesis and their potential clinical implications. Lung Cancer 34(Suppl 2):S27–S34.
  • Mayall FG, Jacobson G, Wilkins R. 1999. Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas. J Clin Pathol 52:291–293.
  • McDonald JW, Taylor JA, Watson MA, Saccomanno G, Devereux TR. 1995. p53 and K-ras in radon-associated lung adenocarcinoma. Cancer Epidemiol Biomarkers Prev 4:791–793.
  • Mitsudomi T, Lam S, Shirakusa T, Gazdar AF. 1993. Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer [see comments]. Chest 104:362–365.
  • Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. 2000. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6:4055–4063.
  • Mor O, Yaron P, Huszar M, Yellin A, Jakobovitz O, Brok-Simoni F, Rechavi G, Reichert N. 1997. Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol 16:9–13.
  • Niklinska W, Burzykowski T, Chyczewski L, Niklinski J. 2001a. Expression of vascular endothelial growth factor VEGF in non-small cell lung cancer NSCLC: association with p53 gene mutation and prognosis. Lung Cancer 34(Suppl 2):S59–S64.
  • Niklinska W, Chyczewski L, Laudanski J, Sawicki B, Niklinski J. 2001b. Detection of P53 abnormalities in non-small cell lung cancer by yeast functional assay. Folia Histochem Cytobiol 39:147–148.
  • Nishizaki M, Fujiwara T, Tanida T, Hizuta A, Nishimori H, Tokino T, Nakamura Y, Bouvet M, Roth JA, Tanaka N. 1999. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res 5:1015–1023.
  • Norell SE. 1955. Workbook of epidemiology. New York: University Press.
  • Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614.
    Direct Link:
  • Onuki N, Wistuba II, Travis WD, Virmani AK, Yashima K, Brambilla E, Hasleton P, Gazdar AF. 1999. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 85:600–607.
    Direct Link:
  • Parkin DM, Bray FI, Devesa SS. 2001. Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8):4–66.
  • Paschke T. 2000. Analysis of different versions of the IARC p53 database with respect to G→T transversion mutation frequencies and mutation hotspots in lung cancer of smokers and non-smokers. Mutagenesis 15:457–458.
  • Paschke T. 2001. Reply to the contribution of Hainault, Olivier and Pfeifer TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. Mutagenesis 16:555–556.
  • Payne S. 2001. “Smoke like a man, die like a man?”: a review of the relationship between gender, sex and lung cancer. Soc Sci Med 53:1067–1080.
  • Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. 2000. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. Br Med J 321:323–329.
  • Ramesh R, Saeki T, Templeton NS, Ji L, Stephens LC, Ito I, Wilson DR, Wu Z, Branch CD, Minna JD, Roth JA. 2001. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 3:337–350.
  • Rodin SN, Rodin AS. 2000. Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci USA 97:12244–12249.
  • Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D. 1996. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985–991.
  • Rothman KJ, Greenland S. 1998. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven Publisher.
  • Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E. 1995. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55:5038–5042.
  • Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, Heussel CP, Kommoss F, Perruchoud AP, Shepherd FA, Fritz MA, Horowitz JA, Huber C, Rochlitz C. 2001. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 19:1750–1758.
  • Shivapurkar N, Wiethege T, Wistuba II, Milchgrub S, Muller KM, Gazdar AF. 2000. Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas. Int J Cancer 85:743–745.
    Direct Link:
  • Slebos RJ, Baas IO, Clement MJ, Offerhaus GJ, Askin FB, Hruban RH, Westra WH. 1998. p53 alterations in atypical alveolar hyperplasia of the human lung. Hum Pathol 29:801–808.
  • Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, Pfeifer GP. 2000. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 92:803–811.
  • Soussi T, Beroud C. 2001. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233–240.
  • Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, Della Porta G, Pierotti MA. 1992. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 52:6079–6082.
  • Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. 1989. p53: A frequent target for genetic abnormalities in lung cancer. Science 246:491–494.
  • Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler Jr., Nieman L, Chrousos G, Pass H, Doppman J. 1991. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 15:529–553.
  • Travis WD, Travis LB, Devesa SS. 1995. Lung cancer. Cancer 75:191–202.
    Direct Link:
  • Vahakangas KH, Bennett WP, Castren K, Welsh JA, Khan MA, Blomeke B, Alavanja MC, Harris CC. 2001. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 61:4350–4356.
  • Vahakangas K. 2003. TP53 mutations in exposed workers. Hum Mutat 21:240–251.
    Direct Link:
  • Vogt U, Zaczek A, Klinke F, Granetzny A, Bielawski K, Falkiewicz B. 2002. p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. J Cancer Res Clin Oncol 128:141–147.
  • Wang X, Christiani DC, Wiencke JK, Fischbein M, Xu X, Cheng TJ, Mark E, Wain JC, Kelsey KT. 1995. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol Biomarkers Prev 4:543–548.
  • Wiethege T, Wesch H, Wegener K, Muller KM, Mehlhorn J, Spiethoff A, Schomig D, Hollstein M, Bartsch H. 1999. German uranium miner study–pathological and molecular genetic findings. German uranium miner study, research group pathology. Radiat Res 152:S52–S55.
  • Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, Samet JM, Srivastava SD, MJ Gazdar AF. 1997. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 89:1366–1372.
  • Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, Gazdar AF. 1999. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18:643–650.
  • Wistuba II, Barry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, Mackay B, Minna JD, Gazdar AF. 2000. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res 6:2604–2610.
  • Yang Q, Wesch H, Mueller KM, Bartsch H, Wegener K, Hollstein M. 2000. Analysis of radon-associated squamous cell carcinomas of the lung for a p53 gene hotspot mutation. Br J Cancer 82:763–766.
  • Yuan A, Yu CJ, Luh KT, Kuo SH, Lee YC, Yang PC. 2002. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol 20:900–910.
  • Zang EA, Wynder EL. 1996. Differences in lung cancer risk between men and women: Examination of the evidence. J Natl Cancer Inst 88:183–192.
  • Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. 1994. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1:5–13.
Get PDF (274K)